Navigation Links
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
Date:9/13/2007

First Patient Enrolled in Pivotal Studies

BETHESDA, Md., Sept. 13 /PRNewswire-FirstCall/ -- Sucampo Pharmaceuticals, Inc. (Nasdaq: SCMP) and Takeda Pharmaceuticals North America, Inc. today announced that the first patient has been enrolled in a Phase III study of lubiprostone (24 mcg, oral gel capsules, twice daily) for the treatment of Opioid-Induced Bowel Dysfunction (OBD). The OBD Pivotal Assessment of Lubiprostone (OPAL) program consists of two 12-week double-blind studies, followed by a nine-month open-label safety extension study. The double-blind studies are expected to enroll approximately 840 patients at up to 190 sites in the United States and Canada and will evaluate the effects of lubiprostone as a treatment for constipation stemming from the use of narcotic medications, such as morphine and codeine, prescribed for chronic pain management.

Lubiprostone, a chloride channel activator developed by Sucampo Pharmaceuticals, is currently approved for the treatment of Chronic Idiopathic Constipation in adults as AMITIZA(R) (24 mcg, oral gel capsules, twice daily) and is under FDA review for Irritable Bowel Syndrome with constipation. AMITIZA is marketed in the United States by Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America.

"Each year, millions of patients who suffer from chronic pain are treated with opiates," said Egilius L. H. Spierings, M.D., Ph.D, Associate Clinical Professor of Neurology at Brigham and Women's Hospital, Harvard Medical School. "Many of these patients frequently develop severe constipation from these powerful analgesics; however, there are currently no approved prescription products available to treat this condition. This study is designed t
'/>"/>

SOURCE Sucampo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
10. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
11. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013  Boehringer Ingelheim will contribute to advancing ... American Thoracic Society International Conference (ATS 2013) in ... – 22. Data will highlight research ... of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® ... compounds for asthma, idiopathic pulmonary fibrosis (IPF) and ...
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
... -- Chindex International, Inc. (NASDAQ: ... care services in China through the operations of United ... and affiliated ambulatory clinics, today announced that the Company ... and first half of 2011, which ended June 30, ...
... Apnex Medical, Inc., received investigational device exemption (IDE) approval ... begin a clinical study to evaluate the safety and ... treat obstructive sleep apnea (OSA). Data from this clinical ... application for the HGNS System to the FDA. ...
Cached Medicine Technology:Chindex International, Inc. to Report Financial Results for the Second Quarter and First Half of 2011 2Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 2Apnex Medical, Inc. Receives FDA Approval for Pivotal Clinical Study for Obstructive Sleep Apnea 3
(Date:5/18/2013)... Morro Bay, CA (PRWEB) May 18, 2013 ... salon , has recently completed a stylish renovation that ... and advanced specialties. , From the ground up, this ... been improved with fresh flooring, soothing colors and comfortable ... have been installed, including an Apilus epilator machine. ...
(Date:5/18/2013)... Spectrum Surgical Instruments will attend the ... Austin, TX where thousands of GI nursing professionals ... , Spectrum Surgical/STERIS will feature its flexible ... capabilities and certified pre-owned equipment. Attendees will also ... instrument care of flexible endoscopes. , Visit ...
(Date:5/18/2013)... Miami, FL (PRWEB) May 18, 2013 ... accessories, is now offering its customers an attractive 25% ... Corkscrew. , Customers can now purchase this ... safe and secure online transactional process. The online store ... from the date of order placement. , A ...
(Date:5/18/2013)... UT (PRWEB) May 18, 2013 Medical device ... orders for its much anticipated mobility aid with its namesake, ... create a hands-free crutch alternative that injured individuals ... broken ankle, for example, can remain active and walk during ... is using its reservation system to ensure those who need ...
(Date:5/17/2013)... 18, 2013. Chronic trauma can inflict lasting damage to ... studies of people with post-traumatic stress disorder, or PTSD, ... in response to stressful tasks, such as recalling a ... threatening face. Now, researchers at NYU School of Medicine ... the brains of combat veterans with PTSD in the ...
Breaking Medicine News(10 mins):Health News:Rio Salon and Spa, a Beauty Salon in Morro Bay, Undergoes Makeover 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2Health News:Now Save 25% on Franmara Dynamo Electric Wine Bottle Opener at Wine World Accessories 2Health News:FlexLeg Begins Offering New Mobility Aid 2Health News:For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests 2
... Jan. 28, 2009 Physical therapists at UT Southwestern ... people recovering from neurological injuries such as strokes and traumatic ... repeatedly practice movements needed to regain arm strength and movement. ... sites testing how the Armeo device, with its virtual environment ...
... with AsthmaWASHINGTON, Jan. 28 St. Louis, MO, is ranked ... to live with asthma in the U.S. (1) - according ... conducted the study. This ranking was determined based on an ... U.S. metro areas. (1) St. Louis was ranked No.1 this ...
... Relocated to Adjacent Proton Site in Warrenville CHICAGO, ... Illinois state approval on its plans to build ... in Warrenville. The Illinois Health Facilities Planning Board ... the project,s Certificate of Need application during today,s ...
... disease that,s harder to control, study says , , TUESDAY, ... of tuberculosis patients in the United States who say ... and difficult to treat than other TB patients, a ... patients aged 15 or older. Of those patients, 28,650 ...
... and Republican Party on Wrong TrackSACRAMENTO, Calif., Jan. 27 ... claimed that the Medicaid Family Planning State Option, a ... millions of women, would cost hundreds of millions of ... misleading attacks and partisan politics, was dropped from the ...
... ReportedCARLSBAD, Calif., Jan. 27 Jenny Craig, Inc. ... management, today announced a voluntary recall of its ... (UPC Code 655447009347) for U.S and P.R. distribution ... MAY2409BLO, MAY2509BLO, MAY2509ALO, MAY2609ALO, & MAY2609BLO, because the ...
Cached Medicine News:Health News:Physical therapists test mechanical arm to help patients recover from stroke, traumatic brain injury 2Health News:Physical therapists test mechanical arm to help patients recover from stroke, traumatic brain injury 3Health News:St. Louis Named Top Asthma Capital for 2009 2Health News:St. Louis Named Top Asthma Capital for 2009 3Health News:St. Louis Named Top Asthma Capital for 2009 4Health News:St. Louis Named Top Asthma Capital for 2009 5Health News:St. Louis Named Top Asthma Capital for 2009 6Health News:Central DuPage Hospital Wins State Approval to Build Cancer Center 2Health News:Central DuPage Hospital Wins State Approval to Build Cancer Center 3Health News:Substance Abuse Hinders TB Treatment 2Health News:Family Planning Provision Wrongfully Removed From Economic Stimulus Package 2Health News:Jenny Craig Announces Nationwide Voluntary Recall of Jenny's Cuisine(R) Anytime Peanut Butter Flavor Nutritional Bars Due to Possible Peanut Corporation of America (PCA) Contamination and Potential Health Risk 2
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
... exchange in endourological procedures. The increased inner ... utilization of an extra heavy duty mandril ... flexible tip. The proximal end of this ... wire guide manufactured by Cook®. Supplied sterile ...
Medicine Products: